On the other hand, an amplified Akt1 is less frequent since it has been found only in 20% of neuroendocrine prostate cancers, 10% of pancreatic cancers, and 3–5% of breast and serous ovarian cancers [42]. This evidence concerns the gene AKT1 and ovarian serous adenocarcinoma.